Brittany Albright, MD, MPH

Psych Congress 2026

September 15–19, 2026 · New Orleans, LA · Full program

• CourseAdvanced Psychopharmacology Intensive: Emerging Neurobiologic Targets and Metabolic Pathways Reshaping Psychiatric Treatment

  September 15, 2026

  Half-day ticketed intensive built around four expert-led modules on treatment mechanisms moving beyond monoamines: orexin-based agents, glutamate/dopamine circuit approaches, muscarinic receptor modulation, and GLP-1/bioenergetic pathways.

  GLP-1 & Metabolic PsychiatryMuscarinic & Novel AntipsychoticsNeuroscience & MechanismsDrug Pipeline & Clinical Trials

• SymposiumMasterClass: Could Glutamatergic Modulation be the Keystone of Durable Change in Treatment-Resistant Depression?

  September 15, 2026

  Examines glutamatergic dysfunction in MDD and the evidence for current and emerging glutamate-targeting therapies in treatment-resistant depression.

  Ketamine & EsketamineNeuroscience & MechanismsTreatment-Resistant Depression

• SymposiumSolving Clinical Challenges: Managing Major Depressive Disorder When First-Line Treatments Fall Short

  September 15, 2026

  Case-based walkthrough of evaluating apparent treatment resistance in MDD — uncovering hidden contributors like anxiety, trauma, and medical illness — and choosing among optimization, augmentation, and switching pathways.

  DepressionTreatment-Resistant Depression

• SymposiumMasterClass: Volition Reignition: Achieving Patient Goals by Detecting and Addressing Anhedonia in MDD

  September 17, 2026

  Focuses on reward-system dysfunction in depression, practical assessment of anhedonia, and emerging therapies aimed at restoring motivation and meaningful recovery.

  DepressionMeasurement-Based Care & DiagnosisNeuroscience & Mechanisms

• SymposiumMasterClass: GAD Care Reimagined: Current Best Practices and the Emerging Role of Psychedelics

  September 18, 2026

  Pairs a review of current GAD standards of care with the therapeutic rationale and emerging evidence for investigational psychedelic compounds in anxiety.

  Anxiety DisordersPsychedelics

• SymposiumMind & Metabolic Matters: Practical Guidance on Prescribing GLP-1s in Psychiatry

  September 19, 2026

  Clinic-ready framework for GLP-1 and dual-incretin use in psychiatric patients: selection, titration, adverse-effect management, and psychiatric considerations including eating disorder risk, mood monitoring, and craving implications.

  Drug Interactions & SafetyEating DisordersGLP-1 & Metabolic Psychiatry